Biofrontera Inc.'s latest 10-Q and supporting filings reveal a pivotal transition after acquiring full U.S. rights to its key products, Ameluz and RhodoLED lamps, in October 2025. This consolidation empowers direct clinical trial oversight and commercial expansion targeting actinic keratosis treatment in dermatology offices nationwide. The firm's business model centers on selling a differentiated photodynamic therapy system directly to clinicians, supported by ongoing R&D for label extensions. While growth engines stem from new indications and expanding the customer base, patent litigation risks and Nasdaq listing price concerns remain key watchpoints ahead of upcoming milestones.